{
    "clinical_study": {
        "@rank": "107775", 
        "arm_group": [
            {
                "arm_group_label": "Treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month"
            }
        ], 
        "brief_summary": {
            "textblock": "The major objective of the present study is to examine the influence of normobaric hyperoxia\n      treatment on the symptoms of patients diagnosed with depression members of Clalit Health\n      Services. The investigators hypothesize that normobaric hyperoxia treatment will improve the\n      symptoms of patients with depression."
        }, 
        "brief_title": "Oxygen Therapy in Depression", 
        "condition": "Depression, Normobaric Hyperoxia.", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Hyperoxia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women aged 18-65 years diagnosed with mild to moderate depression.\n\n        Exclusion Criteria:\n\n          -  Patients with oxygen saturation below 95%;\n\n          -  An unstable mental (psychiatric) condition\n\n          -  A psychiatric condition that requires a change in pharmacotherapy (importantly -\n             medications will not be changed in patients who will be enrolled to the study)\n\n          -  Acute or chronic respiratory disease\n\n          -  Any severe physical illness\n\n          -  Suicidal thoughts or attempts\n\n          -  Drug abuse\n\n          -  Obesity (BMI over 30)\n\n          -  Inability to cease smoking during night hours while participants are supposed to be\n             using the oxygen/air supplementing machine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149563", 
            "org_study_id": "002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment", 
                "Placebo"
            ], 
            "description": "Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.", 
            "intervention_name": "oxygen-enriched air -Normobaric hyperoxia treatment for depression", 
            "intervention_type": "Device", 
            "other_name": "Oxygen-enriched air provided by oxygen concentrators to improve symptoms of patients with depression."
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beer-sheva", 
                    "country": "Israel"
                }, 
                "name": "Clalit Health Services in the Southern region"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Oxygen Therapy in Depression", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HRSD will be used to assess changes in patients' condition. Assessment will be performed at 3 time points: baseline (time zero), 2 weeks and 4 weeks after treatment initiation, by a trained psychiatric nurse blind to the patient's treatment status.", 
            "measure": "Hamilton Rating Scale for Depression (HRSD)-changes in patients' depression.", 
            "safety_issue": "No", 
            "time_frame": "Baseline (time zero), 2 weeks and 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}